Cetuximab
Progression Free Survival
Grupo Hospital de Madridmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Progression Free Survival cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Sun Yat-sen University | Phase 2 | B |
FLUOROURACILUM Karen-Lise Garm Spindler | Phase 2 | B |
Irinotecan Grupo Hospital de Madrid | Phase 2 | B |
Capecitabine Karen-Lise Garm Spindler | Phase 2 | B |
Calcium folinate pentahydrate Karen-Lise Garm Spindler | Phase 2 | CCC |
Azacitidine Sun Yat-sen University | N/A | D |
mln9708 RenJi Hospital | N/A | D |
Tucidinostat Sun Yat-sen University | N/A | D |
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →